Axa boosted its stake in shares of Loxo Oncology Inc (NASDAQ:LOXO) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,836 shares of the biopharmaceutical company’s stock after purchasing an additional 2,201 shares during the quarter. Axa owned about 0.33% of Loxo Oncology worth $8,404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of LOXO. OppenheimerFunds Inc. boosted its position in Loxo Oncology by 62.8% during the fourth quarter. OppenheimerFunds Inc. now owns 1,061,111 shares of the biopharmaceutical company’s stock valued at $89,324,000 after purchasing an additional 409,209 shares in the last quarter. California Public Employees Retirement System acquired a new stake in Loxo Oncology in the fourth quarter worth about $4,249,000. Opaleye Management Inc. boosted its holdings in Loxo Oncology by 35.6% in the fourth quarter. Opaleye Management Inc. now owns 176,300 shares of the biopharmaceutical company’s stock worth $14,841,000 after acquiring an additional 46,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in Loxo Oncology in the third quarter worth about $2,253,000. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Loxo Oncology by 29.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 105,741 shares of the biopharmaceutical company’s stock worth $9,741,000 after acquiring an additional 24,025 shares in the last quarter.
Shares of Loxo Oncology Inc (NASDAQ:LOXO) opened at $132.87 on Wednesday. Loxo Oncology Inc has a twelve month low of $40.52 and a twelve month high of $135.74. The company has a market capitalization of $3,980.00, a PE ratio of -25.36 and a beta of 2.37.
Several equities research analysts have weighed in on LOXO shares. Citigroup lowered their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, November 16th. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Cann reissued a “buy” rating and issued a $122.00 price target on shares of Loxo Oncology in a report on Thursday, March 1st. Stifel Nicolaus reissued a “buy” rating and issued a $135.00 price target on shares of Loxo Oncology in a report on Friday, March 2nd. Finally, Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a report on Friday, March 9th. Eleven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Loxo Oncology has an average rating of “Buy” and a consensus target price of $124.44.
In related news, VP Jennifer Burstein sold 1,700 shares of Loxo Oncology stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $93.24, for a total transaction of $158,508.00. Following the completion of the sale, the vice president now owns 1,700 shares of the company’s stock, valued at $158,508. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $96.57, for a total value of $1,448,550.00. Following the sale, the chief executive officer now directly owns 190,207 shares of the company’s stock, valued at approximately $18,368,289.99. The disclosure for this sale can be found here. Insiders have sold 334,146 shares of company stock valued at $27,668,728 in the last ninety days. Corporate insiders own 27.80% of the company’s stock.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.